Unfortunately, the therapeutic potential of agonists of the CD3/CD28/CD2 signaling pathway is uncertain, given the plethora of undesirable side effects, including transient lymphopenia, previously observed in patients treated with OKT3 antibodies [71], [72]. This evidence concerns the gene CD28 and lymphopenia.